Cellectis' Annual Shareholders General Meeting to be Held on June 28, 2024

Investor Relations contacts: Arthur Stril, Interim Chief Financial Officer, +1 (347) 809 5980, investors@cellectis.com Ashley R. Robinson, LifeSci Advisors, +1 617 430 7577 Attachment Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life- saving cell and gene therapies. Cellectis utilizes an allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patien ...